Johnson & Johnson’s single-dose vaccine protects against COVID-19S, according to an analysis by U Regulators on Wednesday setting the stage for a final decision on a new and more user-friendly shot to tame the pandemic
The Food and Drug Administration scientists confirmed that the vaccine is 66% overall effective at preventing moderate to severe COVID-19, the agency also said that J&J’s shot – one that could help speed vaccinations, by requiring only one dose instead of two – safe to use

This is only one step in the FDAS ‘evaluation of a third vaccine option for U On Friday, the agency’s independent advisors will discuss whether the evidence is strong enough to recommend the long-awaited shot With that advice, the FDA is expected to make a final decision in a matter of days

The vaccination campaign went slower than hoped, hampered by logistical problems and weather delays, despite the country losing more than 500000 virus-related deaths mourn To date, approximately 65 million Americans have received at least one dose of vaccine from Pfizer or Moderna, which requires two doses several weeks apart for complete protection

J&J tested his single-dose option on 44000 people in the USAS, Latin America, and South Africa With different mutant versions of the virus circulating in different countries, the researchers analyzed the results geographically J&J previously announced that the vaccine is working better in the US – 72% effective against moderate to severe COVID-19, compared to 66% in Latin America and 57% in South Africa

Still, it was highly effective against the most serious symptoms in each country, and early study results showed there were no hospitalizations or deaths 28 days after vaccination

While the overall efficacy numbers may suggest the J&J candidate isn’t quite as powerful as two-dose competitors, all COVID-19 vaccines worldwide have been tested differently, making comparisons nearly impossible, while it wouldn’t be surprising if up would find one dose to be slightly weaker than two doses, but policy makers will decide if this is an acceptable compromise to get more people vaccinated faster

J&J was well on its way to becoming the world’s first single-dose option until Mexico announced earlier this month that it would be using a single-dose version of China’s CanSino.This vaccine is made using technology similar to that of J&J, but was originally made Developed as a two-dose option until a one-dose test started in the fall

The vaccines used in the US by rivals Pfizer and ModernaS and numerous other countries must be kept frozen, while the J&J shot can be refrigerated for three months, making it easier to use.AstraZeneca’s vaccine, widely used in Europe, the UK and Israel, is made in a similar manner and also requires refrigeration, but takes two Cans a

If the FDA clears the J&J shot for US Using it will not significantly increase vaccine supply immediately, with only a few million doses expected to be ready for shipment in the first week, J&J told Congress this week that it will have 20 million doses by the end of March and 100 million doses by the summer

European regulators and the World Health Organization are also considering J&J’s vaccine. The company plans to produce around one billion doses worldwide by the end of the year

Get a recap of the most important and fascinating national stories in your inbox every weekday

Get a recap of the most important and fascinating national stories in your inbox every weekday

Johnson and Johnson Vaccine

World News – CA – Johnson & Johnson One-Shot Vaccine Is Safe And Prevents COVID-19, US. FDA says